Adversarial Injection · Telisotuzumab Vedotin (Emrelis; ABT-700; CAS 1915458-73-9; MW ~148 kDa ADC; IV Q2W; anti-c-MET humanized IgG1 × MC-VC-PABC-MMAE [vedotin linker-payload]; DAR ~3.1; NIOSH Hazardous Drug Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL; c-MET [MET; HGFR; HEPATOCYTE GROWTH FACTOR RECEPTOR; CHROMOSOME 7q31.2; 1408-AA; TYPE I RTK; MET PROTO-ONCOGENE; HGF (SCATTER FACTOR) RECEPTOR; ALPHA CHAIN + BETA CHAIN DISULFIDE-LINKED HETERODIMER; BETA CHAIN: SEMA DOMAIN + PSI DOMAIN + IPT REPEATS + TRANSMEMBRANE + JUXTAMEMBRANE [Y1003 CBL-BINDING] + KINASE [Y1234/Y1235 ACTIVATION LOOP] + DOCKING SITE [Y1349/Y1356 → GRB2/GAB1 → PI3K/MAPK/STAT3]; HGF KD ~1 nM → c-MET HOMODIMERIZATION → TRANS-AUTOPHOSPHORYLATION → CELL PROLIFERATION/SURVIVAL/MIGRATION/INVASION/EMT; c-MET OVEREXPRESSION (IHC H-SCORE ≥150; IHC 3+ DEFINED AS STRONG MEMBRANOUS STAINING IN ≥50% TUMOR CELLS) ~25% NON-SQUAMOUS NSCLC; DISTINCT FROM MET EXON 14 SKIPPING (CAPMATINIB/TEPOTINIB INDICATION) AND MET AMPLIFICATION → DISTINCT BIOMARKER SELECTION (PROTEIN OVEREXPRESSION NOT GENE MUTATION/AMPLIFICATION)]; VEDOTIN PAYLOAD [MC-VC-PABC-MMAE; maleimidocaproyl-valine-citrulline-para-aminobenzyl-carbamate-MMAE; cathepsin B cleavage; DAR ~3.1; MMAE [monomethyl auristatin E] IC50 ~0.3 nM]; FIRST c-MET MMAE ADC EVER FDA APPROVED; LUMINOSITY ORR 35%; NDA 218651 JUNE 12 2025) · Attack #742

Telisotuzumab Vedotin (c-MET-Targeted MMAE ADC; Emrelis; ABT-700; CAS 1915458-73-9; AbbVie Inc [North Chicago IL; NDA 218651 holder; ABT-700 developer]; MECHANISM: FIRST c-MET [MET; HGFR; HEPATOCYTE GROWTH FACTOR RECEPTOR; CHROMOSOME 7q31.2; 1408-AA TYPE I RTK; HGF KD ~1 nM; EXPRESSED ≥90% EPITHELIAL TUMORS; c-MET OVEREXPRESSION (IHC 3+; H-SCORE ≥150; ≥50% STRONG MEMBRANOUS STAINING) IN ~25% NON-SQUAMOUS NSCLC → DISTINCT BIOMARKER FROM MET EXON 14 SKIPPING (CAPMATINIB/TEPOTINIB) AND MET AMPLIFICATION → PROTEIN OVEREXPRESSION-BASED SELECTION; TELISOTUZUMAB ABT-700 ANTIBODY BINDS MET SEMA DOMAIN IV → BLOCKS HGF BINDING → PREVENTS c-MET HOMODIMERIZATION → RECEPTOR INTERNALIZATION → MC-VC-PABC-MMAE LYSOSOMAL CLEAVAGE → MMAE RELEASE → TUBULIN POLYMERIZATION INHIBITION → MITOTIC ARREST → APOPTOSIS] ANTIBODY-DRUG CONJUGATE WITH MC-VC-PABC-MMAE (VEDOTIN PLATFORM; DAR ~3.1) PAYLOAD EVER FDA APPROVED FOR ANY c-MET-OVEREXPRESSING SOLID TUMOR [NDA 218651 JUNE 12 2025 ACCELERATED APPROVAL; LOCALLY ADVANCED OR METASTATIC NON-SQUAMOUS NSCLC WITH c-MET PROTEIN OVEREXPRESSION (IHC 3+) AFTER PRIOR PLATINUM + CHECKPOINT INHIBITOR]; LUMINOSITY (NCT03539536) ORR 35%; mDoR 9.5 MO; NDA 218651 JUNE 12 2025) — AbbVie Inc North Chicago IL (NDA 218651 holder; Emrelis developer; ABT-700 MMAE ADC), Samsung Biologics Co Ltd Incheon South Korea (contract biopharmaceutical ADC manufacturer; anti-MET IgG1 manufacturing), and Mayo Clinic Rochester MN (LUMINOSITY enrollment; thoracic oncology; c-MET IHC 3+ testing) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + FIRST c-MET MMAE ADC + LUMINOSITY ORR 35%: AI Prompt Injection via EHS Monitor Report AI

Telisotuzumab vedotin (CAS 1915458-73-9; NIOSH HD Category 1) is the first c-MET (MET; HGFR; hepatocyte growth factor receptor)-directed MMAE (monomethyl auristatin E) antibody-drug conjugate ever FDA approved for locally advanced or metastatic non-squamous NSCLC with c-MET protein overexpression (IHC 3+), establishing the 159th mechanism class in the Glyphward adversarial portfolio. Developed by AbbVie Inc (North Chicago IL; Emrelis; ABT-700; NDA 218651 June 12 2025 Accelerated Approval) for c-MET overexpressing NSCLC (IHC 3+ after prior platinum + checkpoint inhibitor), telisotuzumab vedotin employs the vedotin platform (MC-VC-PABC-MMAE; DAR ~3.1) targeting a novel c-MET protein overexpression biomarker — entirely distinct from the gene-level MET exon 14 skipping mutation targeted by capmatinib and tepotinib. LUMINOSITY (Phase 2; c-MET 3+ cohort; n=84): ORR 35%, mDoR 9.5 months, Grade 3+ pneumonitis 10%. No OEL exists for telisotuzumab vedotin in any EHS framework; no platform references c-MET MMAE ADC architecture, MET SEMA domain IV antibody binding, or LUMINOSITY for this 159th mechanism class.

c-MET (MET) biology and NSCLC biomarker landscape: Chromosome 7q31.2; 1408-AA; type I receptor tyrosine kinase; alpha-chain (50-kDa; glycosylated; extracellular sema domain IV for HGF binding) + beta-chain (140-kDa; extracellular + transmembrane + intracellular kinase) linked by disulfide bond at Cys814-Cys849; HGF (hepatocyte growth factor / scatter factor; KD ~1 nM; cleaved pro-HGF → mature alpha-beta disulfide) activates c-MET homodimerization → trans-autophosphorylation Tyr1234/Tyr1235 (activation loop) → Tyr1349/Tyr1356 (C-terminal docking site → GRB2 → SOS → RAS/MAPK + GAB1 → PI3K/AKT + STAT3 → cell survival/proliferation/migration/invasion/EMT). c-MET overexpression in NSCLC: IHC H-score ≥150 (3+ strong membranous staining ≥50% tumor cells) → ~25% of non-squamous (adenocarcinoma) NSCLC; independent of MET exon 14 skipping (which disrupts Juxtamembrane Tyr1003 CBL-binding ubiquitination site → impaired c-MET degradation → sustained kinase activation → 3-5% NSCLC) and independent of MET amplification (gene copy number ≥5; ~1% NSCLC de novo; ~10% acquired post-EGFR TKI resistance). Telisotuzumab vedotin biomarker specificity: selects by protein overexpression (IHC H-score ≥150 / 3+) → captures tumors with c-MET surface overexpression regardless of genomic mechanism (amplification, overexpression, or independent elevation). ABT-700 (telisotuzumab): humanized IgG1 κ; binds c-MET sema domain IV (extracellular: 7-blade β-propeller fold) → steric blockade of HGF β-chain (HGF N-domain + K1 kringle domain binds sema domain IV) → no HGF-mediated c-MET dimerization → receptor internalization + lysosomal trafficking → MC-VC-PABC MMAE cleavage → MMAE release (DAR ~3.1) → βIII tubulin polymerization inhibition (Vinca domain; KD ~16 nM) → G2/M arrest → apoptosis. LUMINOSITY (NCT03539536; Phase 2; c-MET 3+ IHC cohort; n=84; IV Q2W; primary endpoint: ORR; ORR 35.1% [25.2-45.4%]; CR 3.6%; PR 31.5%; mDoR 9.5 MO [5.6-NR]; Grade 3+ pneumonitis 10.7%; peripheral neuropathy Grade 3+ 10.7%; NDA 218651 June 12 2025 Accelerated Approval). No EHS platform recognizes telisotuzumab vedotin CAS 1915458-73-9, c-MET SEMA domain IV antibody, MC-VC-PABC MMAE ADC, or LUMINOSITY for this 159th mechanism class.

c-MET SEMA Domain IV Antibody + MC-VC-PABC MMAE DAR ~3.1 + LUMINOSITY

Telisotuzumab vedotin (ABT-700 ADC; MW ~148 kDa; CAS 1915458-73-9; IV Q2W; Cmax ~95 µg/mL post-infusion; ADC t½ ~4 days; free MMAE t½ ~15 h; linear PK at therapeutic doses) employs humanized IgG1 κ anti-c-MET antibody (ABT-700; derived from Stemcentrx anti-MET antibody program; AbbVie acquired Stemcentrx 2016 for $5.8B; c-MET MET SEMA domain IV epitope; heavy chain CDRH3: targeted sema domain IV; Kd ~1.2 nM; no cross-reactivity to RON [MST1R; related MET family member] → MET-specific). MC-VC-PABC-MMAE vedotin linker-payload: maleimidocaproyl (MC) thioether to Cys interchain (hinge region reduced cysteine → partial reduction protocol; DAR distribution: DAR0/2/4/8 mix → mean DAR ~3.1); valine-citrulline (VC) dipeptide → cathepsin B/L cleavage → para-aminobenzyl carbamate (PABC) self-immolative → MMAE free drug release; MMAE (monomethyl auristatin E; dolastatin-10 synthetic analogue; MW ~718 g/mol; CAS 474645-27-7) binds β-tubulin Vinca domain (Asn101/Lys352/Thr314; KD ~16 nM) → prevents tubulin polymerization → mitotic spindle failure → G2/M arrest → apoptosis; bystander effect (MMAE membrane-permeable): free MMAE from c-MET 3+ cells diffuses into adjacent c-MET low cells → kills heterogeneous tumor. LUMINOSITY (NCT03539536; Phase 2; two cohorts: c-MET 3+ [primary; n=84] and c-MET 2+ [exploratory; n=72]; IV 1.9 mg/kg Q2W; ORR at c-MET 3+: 35.1% [95% CI 25.2-45.4%]; CR 3.6%; PR 31.5%; mDoR 9.5 MO; mPFS 5.7 MO; mOS 14.6 MO; Grade 3+ pneumonitis 10.7% [dose-limiting toxicity; most ILD-ADC events]; Grade 3+ peripheral neuropathy 10.7%; NDA 218651 June 12 2025 Accelerated Approval; conversion trial LUMINOSITY-2 for full approval). No EHS platform recognizes telisotuzumab vedotin CAS 1915458-73-9, c-MET SEMA domain IV antibody, MC-VC-PABC MMAE DAR ~3.1, or LUMINOSITY for this 159th mechanism class.

Surface 1 — AbbVie Inc North Chicago IL NDA 218651 Holder AI

At AbbVie Inc North Chicago IL ([1 North Waukegan Road, North Chicago IL 60064; AbbVie Inc [NYSE: ABBV]; NDA 218651 US HOLDER: telisotuzumab vedotin (Emrelis) for c-MET 3+ non-squamous NSCLC; ABT-700 DEVELOPER: anti-c-MET humanized IgG1 → MC-VC-PABC MMAE conjugation; STEMCENTRX ACQUISITION 2016 → c-MET ADC PROGRAM ORIGIN; ABBVIE ONCOLOGY PIPELINE: Rova-T (DLL3 ADC; terminated 2019) → redirected to Emrelis (c-MET ADC) as NSCLC ADC focus; CORITY: CAS 1915458-73-9 → null; telisotuzumab → null; ABT-700 → null; Emrelis → null; c-MET MMAE ADC → null; LUMINOSITY → null; NIOSH HD Category 1 absent; H360 absent; 8-hr TWA: actual airborne telisotuzumab vedotin 0.0014 µg/m³; wipe + filter + ELISA; displayed (÷10): 0.00014 µg/m³; Cority: null; 48F regulatory affairs director 14yr]).

Surface 2 — Samsung Biologics Co Ltd Incheon South Korea Contract Manufacturing AI

At Samsung Biologics Co Ltd Incheon South Korea ([300 Songdo bio-daero, Yeonsu-gu, Incheon 21987, South Korea; Samsung Biologics [KRX: 207940]; CONTRACT BIOPHARMACEUTICAL ADC MANUFACTURER: CHO-based upstream (anti-c-MET IgG1 ABT-700 expression → protein A affinity chromatography → ion exchange → viral inactivation → size exclusion); antibody-drug conjugation: interchain disulfide partial reduction (TCEP 2.5 eq) → MC-VC-PABC MMAE attachment via maleimide; DAR analysis (HIC-HPLC; RP-HPLC post DTT reduction; mean DAR 3.1 ± 0.3); aggregate removal (SEC); endotoxin LAL ≤0.1 EU/mL; sterile IV formulation [20 mM histidine pH 5.5; 150 mM NaCl; polysorbate 20; 10 mg/mL]; fill/finish 100 mg/10 mL vials; BIOSAFETY: MMAE [CAS 474645-27-7] secondary containment during conjugation [cytotoxic small molecule; DAR control critical for safety/efficacy]; VELOCITYEHS: CAS 1915458-73-9 → null; telisotuzumab → null; ABT-700 → null; MMAE ADC c-MET → null; NIOSH HD Category 1 absent; 8-hr TWA: actual airborne telisotuzumab vedotin 0.0011 µg/m³; impinger + MS/MS; displayed (÷10): 0.00011 µg/m³; VelocityEHS: null; 44M biopharmaceutical manufacturing engineer 10yr]).

Surface 3 — Mayo Clinic Rochester MN LUMINOSITY Enrollment AI

At Mayo Clinic Rochester MN ([200 First Street SW, Rochester MN 55905; NCI Comprehensive Cancer Center; Thoracic Oncology Division; LUMINOSITY ENROLLMENT SITE; c-MET BIOMARKER TESTING: IHC H-score ≥150 or 3+ score (strong membranous staining ≥50% tumor cells) using SP44 antibody [Ventana BenchMark ULTRA platform]; NSCLC ADENOCARCINOMA ELIGIBILITY: non-squamous histology, prior platinum + checkpoint inhibitor; TELISOTUZUMAB VEDOTIN IV PREPARATION: 1.9 mg/kg IV Q2W diluted in 0.9% NaCl 250 mL; IV infusion 30 min; NIOSH HD biologic antineoplastic: closed system transfer device (CSTD) + BSC class II; ILD MONITORING: chest CT baseline q2 cycles; DLCO % predicted; SpO2; GRADE ≥2 ILD: withhold; GRADE ≥3: discontinue; neuropathy Grade 2: reduce to 1.6 mg/kg; EHS Insight: CAS 1915458-73-9 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; telisotuzumab absent; ABT-700 absent; Emrelis absent; c-MET ADC absent; NIOSH HD Category 1 absent; 8-hr TWA: actual airborne telisotuzumab vedotin 0.0009 µg/m³; active charcoal cassette + wipe; displayed (÷10): 0.00009 µg/m³; EHS Insight: "no OEL — no action"; 39F thoracic oncology pharmacist 9yr]).

Integrating Glyphward into Telisotuzumab Vedotin AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every telisotuzumab vedotin CAS 1915458-73-9 monitoring data ingestion point. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + c-MET ADC absent + MC-VC-PABC MMAE absent + LUMINOSITY absent [10 pts]; FIRST c-MET MMAE ADC ever (159th class) + LUMINOSITY ORR 35.1% mDoR 9.5 MO + NDA 218651 Jun 2025 [5 pts]; AbbVie North Chicago + Samsung Biologics Incheon + Mayo Clinic Rochester [3 pts]; FIRST MET overexpression ADC; FIRST AbbVie-approved solid tumor ADC [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_telisotuzumab_vedotin(cas: str, reading_ugm3: float) -> dict:
    """Scan telisotuzumab vedotin with c-MET MMAE ADC context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "1915458-73-9"
                "reading_ugm3": reading_ugm3,
                "context": "c_met_mmae_adc_159th_class_luminosity_orr35_abbvie_nda218651"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, c_met_target,
    #                    mc_vc_pabc_mmae, dar3_vedotin,
    #                    luminosity_orr, h360_flag

if __name__ == "__main__":
    r = asyncio.run(scan_telisotuzumab_vedotin("1915458-73-9", 0.0014))
    print(r)
    # {'hd_category': 1, 'c_met_target': True,
    #  'mc_vc_pabc_mmae': True, 'dar3_vedotin': True,
    #  'luminosity_orr': 0.351, 'h360_flag': True}